Pengaruh Iklim Organisasi dan Kualitas Kehidupan Kerja terhadap Kinerja Pegawai Dinas Sosial Provinsi Bali

Penelitian ini bertujuan untuk mengetahui pengaruh iklim organisasi dan kualitas kehidupan kerja terhadap kinerja pegawai. Model penentuan sampel pada penelitian ini menggunakan sampel jenuh, dimana responden berjumlah 71 orang. Alat analisis yang digunakan dalam penelitian ini yaitu analisis regresi linear berganda. Hasil yang diperoleh dalam penelitian ini adalah iklim organisasi tidak berpengaruh signifikan terhadap kinerja pegawai dan kualitas kehidupan kerja berpengaruh signifikan terhadap kinerja pegawai. Hendaknya pimpinan mampu menciptakan suasana yang aman dan nyaman yang membuat terjalinnya komunikasi yang baik antara pimpinan dan pegawai. Pimpinan sebaiknya memberikan kesempatan para pegawai dalam menangani masalah baru yang akan menambah pengalaman mereka. Instansi juga memberikan kesempatan pada pegawai untuk mengikuti diklat yang akan membuat mereka semakin betah untuk bekerja di suatu organisasi

Perancangan Model Integrasi Manajemen Kebijakan Outsourcing Dalam Perspektif Hubungan Industrial

. This research objective is to design an outsourcing policy management integration model in industrial relation perspective in order to harmonize social, cultural, economic and legal aspects. The model is expected to improve welfare for workers, profit for industrial development, and provide benefit for the government.This research was initiated by field observation to analyze empirical condition on current outsourcing practices from the view of industries, government, and the workforce themselves along with their labor union. The result of problem identification was then analyzed to obtain outsourcing policy management integration model in order to build harmonious industrial relation. The method used was Soft System Methodology (SSM). Data were collected through FGD, IDI, and expert survey. Technique analysis was conducted through analysis CATWOE (Customer, Actor, Transformation, World-view, Owner, Environment constraint ), Analytical Network Process (ANP), Strategic Assumption Surfacing and Testing (SAST), through SSM Learning Models aiming to design Purposeful Activity Models (PAM). The Integration Management of Outsourcing Policy Model to perfom comprehensive management outsourcing system involving stakeholders in planning, supervision, guidance and enforcement to minimize conflict. The implication of modeling result is strong industrial relation trilogy; namely welfare for workers, security and sustainability for companies, conducive climate and benefits for the government

Effectiveness of bioactive combinations of several plant substances to inhibit the growth of Escherichia coli and Salmonella sp.

The use of antibiotic growth promoters (AGP) has been banned as feed additives in many countries, therefore the alternatives need to be found.  An in vitro experiment  was conducted to study the potential of combination of some plant extract to inhibit growth of pathogen bateria that normally occur in the poultry gastro intestinal tract.The combination of three plants bioactives (liquid smoke of cashew shells of Anacardium occidentaleor CLS, Phyllanthus niruri L. extract (EM), and Synzygium aromaticum extract (EDC) were formulated and evaluated for its effectiveness to inhibit growth of Escherichia coli and Salmonella sp. in vitro.The mixtures (KE) were then made in 3 different concentrations, i.e. 100 % KE, 50% KE, and 25% KE and studied their effectiveness to inhibit growth of E. coli or Salmonella sp. using microplate reader method. The results showed that the higher the concentration of the bioactive combination (KE100) the higher the ability to inhibit the growth of E. coli or Salmonella sp. The combination of bioactive substances CAM, EM, and EDC more effectively than Zn-bacitracin antibiotics to inhibit the growth of E. coli and Salmonella sp. The optimum concentration of KE with the similar effectiveness as the AGP was 25%. It was concluded that the combination of CAM, EM, and EDC was able to inhibit the growth of E. coli and even capable to eliminate the presence of Salmonella sp. In the biological assay, a combination of CAM, EM, and EDC either extract or powder form, high dose, medium or low does not affect the weight of the spleen, bursa fabricius, and blood profile. The best combination of CAM, EM, and EDC extracts to decreases the total bacterial population and E. coli was middle dose ie 0.0625% (extract) and 0.625% (powder). Likewise for live weight gain that was a good dose of extract or powder form can replace antibiotics. It was concluded that combinations of CAM, EM, and EDC had potential as a substitute for AGP in poultry feed, especially chickens

Satellite observed oceanographic drivers of Mobulidae fisheries catch in the Southeast Indian Ocean

\ua9 2024 The Authors. Indonesian coastal waters include several marine megafauna biodiversity hotspots. Several fish populations of ecological and socio-economic importance, such as elasmobranchs (sharks and rays), have experienced rapid decline due to unsustainable human activities, primarily overfishing. Small-scale fisheries (SSF) are currently exempt from governmental fisheries management measures despite contributing a significant proportion of a total catch. The Generalised Additive Models were used to investigate the effect of variations in oceanographic parameters of the Teluk Penyu fishing ground, south of central Java, on the magnitude of Mobulidae (Mobula spp.) catch based on its landings data over ten years (2009–2018) from one of Indonesia\u27s largest ports, Cilacap, Central Java, Indonesia. Mobulidae catch from Teluk Penyu fishing ground was generally higher from June to November when the water exhibited relatively high sea surface salinity (sal >34.1 ‰), chlorophyll (0.32–0.45 mg/m3), and nitrate (nit >0.0045 mg NO3/m3), water speed (>0.29 m/s) and eddy kinetic energy (>0.04 m3/s2) levels, and relatively low sea surface temperature (<28 \ub0C), oxygen (<0.182 mg O2/m3) and sea surface height (<0.9 m) levels than the other months of the year. This study reveals that satellite Earth Observation (EO) data provided a preliminary relationship between oceanographic conditions and the amount of catch for developing more effective management and conservation measures for endangered species like Mobulidae. Utilizing EO data may also be applied to help inform much-needed ecosystem-based management measures, including habitat protection and bycatch reduction for conserving endangered Mobulidae species in the Southeast Indian Ocean. The in-situ onboard ocean observation and temporal species-specific catch data will greatly complement the current work

Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis

Background: Primaquine is used to eliminate Plasmodium vivax hypnozoites, but its optimal dosing regimen remains unclear. We undertook a systematic review and individual patient data meta-analysis to investigate the efficacy and tolerability of different primaquine dosing regimens to prevent P vivax recurrence. Methods: For this systematic review and individual patient data meta-analysis, we searched MEDLINE, Web of Science, Embase, and Cochrane Central for prospective clinical studies of uncomplicated P vivax from endemic countries published between Jan 1, 2000, and June 8, 2023. We included studies if they had active follow-up of at least 28 days, and if they included a treatment group with daily primaquine given over multiple days, where primaquine was commenced within 7 days of schizontocidal treatment and was given alone or coadministered with chloroquine or one of four artemisinin-based combination therapies (ie, artemether–lumefantrine, artesunate–mefloquine, artesunate–amodiaquine, or dihydroartemisinin–piperaquine). We excluded studies if they were on prevention, prophylaxis, or patients with severe malaria, or if data were extracted retrospectively from medical records outside of a planned trial. For the meta-analysis, we contacted the investigators of eligible trials to request individual patient data and we then pooled data that were made available by Aug 23, 2021. We assessed the effects of total dose and duration of primaquine regimens on the rate of first P vivax recurrence between day 7 and day 180 by Cox's proportional hazards regression (efficacy analysis). The effect of primaquine daily dose on gastrointestinal symptoms on days 5–7 was assessed by modified Poisson regression (tolerability analysis). The study was registered with PROSPERO, CRD42019154470. Findings: Of 226 identified studies, 23 studies with patient-level data from 6879 patients from 16 countries were included in the efficacy analysis. At day 180, the risk of recurrence was 51·0% (95% CI 48·2–53·9) in 1470 patients treated without primaquine, 19·3% (16·9–21·9) in 2569 patients treated with a low total dose of primaquine (approximately 3·5 mg/kg), and 8·1% (7·0–9·4) in 2811 patients treated with a high total dose of primaquine (approximately 7 mg/kg), regardless of primaquine treatment duration. Compared with treatment without primaquine, the rate of P vivax recurrence was lower after treatment with low-dose primaquine (adjusted hazard ratio 0·21, 95% CI 0·17–0·27; p<0·0001) and high-dose primaquine (0·10, 0·08–0·12; p<0·0001). High-dose primaquine had greater efficacy than low-dose primaquine in regions with high and low relapse periodicity (ie, the time from initial infection to vivax relapse). 16 studies with patient-level data from 5609 patients from ten countries were included in the tolerability analysis. Gastrointestinal symptoms on days 5–7 were reported by 4·0% (95% CI 0·0–8·7) of 893 patients treated without primaquine, 6·2% (0·5–12·0) of 737 patients treated with a low daily dose of primaquine (approximately 0·25 mg/kg per day), 5·9% (1·8–10·1) of 1123 patients treated with an intermediate daily dose (approximately 0·5 mg/kg per day) and 10·9% (5·7–16·1) of 1178 patients treated with a high daily dose (approximately 1 mg/kg per day). 20 of 23 studies included in the efficacy analysis and 15 of 16 in the tolerability analysis had a low or unclear risk of bias. Interpretation: Increasing the total dose of primaquine from 3·5 mg/kg to 7 mg/kg can reduce P vivax recurrences by more than 50% in most endemic regions, with a small associated increase in gastrointestinal symptoms. Funding: Australian National Health and Medical Research Council, Bill & Melinda Gates Foundation, and Medicines for Malaria Venture

Interactions between marine megafauna and plastic pollution in Southeast Asia

This is the author accepted manuscript. The final version is available from Elsevier via the DOI in this record Southeast (SE) Asia is a highly biodiverse region, yet it is also estimated to cumulatively contribute a third of the total global marine plastic pollution. This threat is known to have adverse impacts on marine megafauna, however, understanding of its impacts has recently been highlighted as a priority for research in the region. To address this knowledge gap, a structured literature review was conducted for species of cartilaginous fishes, marine mammals, marine reptiles, and seabirds present in SE Asia, collating cases on a global scale to allow for comparison, coupled with a regional expert elicitation to gather additional published and grey literature cases which would have been omitted during the structured literature review. Of the 380 marine megafauna species present in SE Asia, but also studied elsewhere, we found that 9.1 % and 4.5 % of all publications documenting plastic entanglement (n = 55) and ingestion (n = 291) were conducted in SE Asian countries. At the species level, published cases of entanglement from SE Asian countries were available for 10 % or less of species within each taxonomic group. Additionally, published ingestion cases were available primarily for marine mammals and were lacking entirely for seabirds in the region. The regional expert elicitation led to entanglement and ingestion cases from SE Asian countries being documented in 10 and 15 additional species respectively, highlighting the utility of a broader approach to data synthesis. While the scale of the plastic pollution in SE Asia is of particular concern for marine ecosystems, knowledge of its interactions and impacts on marine megafauna lags behind other areas of the world, even after the inclusion of a regional expert elicitation. Additional funding to help collate baseline data are critically needed to inform policy and solutions towards limiting the interactions of marine megafauna and plastic pollution in SE Asia.National Research Foundation, Prime Minister’s Office (Singapore) and the Natural Environment Research Council (United Kingdom)National Research Foundation, Prime Minister’s Office (Singapore) and the Natural Environment Research Council (United Kingdom

The efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine with and without primaquine on Plasmodium vivax recurrence: A systematic review and individual patient data meta-analysis

BACKGROUND Artemisinin-based combination therapy (ACT) is recommended for uncomplicated Plasmodium vivax malaria in areas of emerging chloroquine resistance. We undertook a systematic review and individual patient data meta-analysis to compare the efficacies of dihydroartemisinin-piperaquine (DP) and artemether-lumefantrine (AL) with or without primaquine (PQ) on the risk of recurrent P. vivax. METHODS AND FINDINGS Clinical efficacy studies of uncomplicated P. vivax treated with DP or AL and published between January 1, 2000, and January 31, 2018, were identified by conducting a systematic review registered with the International Prospective Register of Systematic Reviews (PROSPERO): CRD42016053310. Investigators of eligible studies were invited to contribute individual patient data that were pooled using standardised methodology. The effect of mg/kg dose of piperaquine/lumefantrine, ACT administered, and PQ on the rate of P. vivax recurrence between days 7 and 42 after starting treatment were investigated by Cox regression analyses according to an a priori analysis plan. Secondary outcomes were the risk of recurrence assessed on days 28 and 63. Nineteen studies enrolling 2,017 patients were included in the analysis. The risk of recurrent P. vivax at day 42 was significantly higher in the 384 patients treated with AL alone (44.0%, 95% confidence interval [CI] 38.7-49.8) compared with the 812 patients treated with DP alone (9.3%, 95% CI 7.1-12.2): adjusted hazard ratio (AHR) 12.63 (95% CI 6.40-24.92), p < 0.001. The rates of recurrence assessed at days 42 and 63 were associated inversely with the dose of piperaquine: AHRs (95% CI) for every 5-mg/kg increase 0.63 (0.48-0.84), p = 0.0013 and 0.83 (0.73-0.94), p = 0.0033, respectively. The dose of lumefantrine was not significantly associated with the rate of recurrence (1.07 for every 5-mg/kg increase, 95% CI 0.99-1.16, p = 0.0869). In a post hoc analysis, in patients with symptomatic recurrence after AL, the mean haemoglobin increased 0.13 g/dL (95% CI 0.01-0.26) for every 5 days that recurrence was delayed, p = 0.0407. Coadministration of PQ reduced substantially the rate of recurrence assessed at day 42 after AL (AHR = 0.20, 95% CI 0.10-0.41, p < 0.001) and at day 63 after DP (AHR = 0.08, 95% CI 0.01-0.70, p = 0.0233). Results were limited by follow-up of patients to 63 days or less and nonrandomised treatment groups. CONCLUSIONS In this study, we observed the risk of P. vivax recurrence at day 42 to be significantly lower following treatment with DP compared with AL, reflecting the longer period of post-treatment prophylaxis; this risk was reduced substantially by coadministration with PQ. We found that delaying P. vivax recurrence was associated with a small but significant improvement in haemoglobin. These results highlight the benefits of PQ radical cure and also the provision of blood-stage antimalarial agents with prolonged post-treatment prophylaxis

Primaquine for uncomplicated Plasmodium vivax malaria in children younger than 15 years: a systematic review and individual patient data meta-analysis.

BACKGROUND: Primaquine, the only widely available treatment to prevent relapsing Plasmodium vivax malaria, is produced as 15 mg tablets, and new paediatric formulations are being developed. To inform the optimal primaquine dosing regimen for children, we aimed to determine the efficacy and safety of different primaquine dose strategies in children younger than 15 years. METHODS: We undertook a systematic review (Jan 1, 2000-July 26, 2024) for P vivax efficacy studies with at least one treatment group that was administered primaquine over multiple days, that enrolled children younger than 15 years, that followed up patients for at least 28 days, and that had data available for inclusion by June 30, 2022. Patients were excluded if they were aged 15 years or older, presented with severe malaria, received adjunctive antimalarials within 14 days of diagnosis, commenced primaquine more than 7 days after starting schizontocidal treatment, had a protocol violation in the original study, or were missing data on age, sex, or primaquine dose. Available individual patient data were collated and standardised. To evaluate efficacy, the risk of recurrent P vivax parasitaemia between days 7 and 180 was assessed by time-to-event analysis for different total mg/kg primaquine doses (low total dose of ∼3·5 mg/kg and high total dose of ∼7 mg/kg). To evaluate tolerability and safety, the following were assessed by daily mg/kg primaquine dose (low daily dose of ∼0·25 mg/kg, intermediate daily dose of ∼0·5 mg/kg, and high daily dose of ∼1 mg/kg): gastrointestinal symptoms (vomiting, anorexia, or diarrhoea) on days 5-7, haemoglobin decrease of at least 25% to less than 7g/dL (severe haemolysis), absolute change in haemoglobin from day 0 to days 2-3 or days 5-7, and any serious adverse events within 28 days. This study is registered with PROSPERO, CRD42021278085. FINDINGS: In total, 3514 children from 27 studies and 15 countries were included. The cumulative incidence of recurrence by day 180 was 51·4% (95% CI 47·0-55·9) following treatment without primaquine, 16·0% (12·4-20·3) following a low total dose of primaquine, and 10·2% (8·4-12·3) following a high total dose of primaquine. The hazard of recurrent P vivax parasitaemia in children younger than 15 years was reduced following primaquine at low total doses (adjusted hazard ratio [HR] 0·17, 95% CI 0·11-0·25) and high total doses (0·09, 0·07-0·12), compared with no primaquine. In 525 children younger than 5 years, the relative rates of recurrence were also reduced, with an adjusted HR of 0·33 (95% CI 0·18-0·59) for a low total dose and 0·13 (0·08-0·21) for a high total dose of primaquine compared with no primaquine. The rate of recurrence following a high total dose was reduced compared with a low dose in children younger than 15 years (adjusted HR 0·54, 95% CI 0·35-0·85) and children younger than 5 years (0·41, 0·21-0·78). Compared with no primaquine, children treated with any dose of primaquine had a greater risk of gastrointestinal symptoms on days 5-7 after adjustment for confounders, with adjusted risks of 3·9% (95% CI 0-8·6) in children not treated with primaquine, 9·2% (0-18·7) with a low daily dose of primaquine, 6·8% (1·7-12·0) with an intermediate daily dose of primaquine, and 9·6% (4·8-14·3) with a high daily dose of primaquine. In children with 30% or higher glucose-6-phosphate dehydrogenase (G6PD) activity, there were few episodes of severe haemolysis following no primaquine (0·4%, 95% CI 0·1-1·5), a low daily dose (0·0%, 0·0-1·6), an intermediate daily dose (0·5%, 0·1-1·4), or a high daily dose (0·7%, 0·2-1·9). Of 15 possibly drug-related serious adverse events in children, two occurred following a low, four following an intermediate, and nine following a high daily dose of primaquine. INTERPRETATION: A high total dose of primaquine was highly efficacious in reducing recurrent P vivax parasitaemia in children compared with a low dose, particularly in children younger than 5 years. In children treated with high and intermediate daily primaquine doses compared with low daily doses, there was no increase in gastrointestinal symptoms or haemolysis (in children with 30% or higher G6PD activity), but there were more serious adverse events. FUNDING: Medicines for Malaria Venture, Bill & Melinda Gates Foundation, and Australian National Health and Medical Research Council